 |
Engineered variant of recombinant human fibroblast growth factor 19 |
|---|---|
| Trade Name | |
| Orphan Indication | Primary biliary cirrhosis |
| USA Market Approval | USA |
| USA Designation Date | 2014-02-06 00:00:00 |
| Sponsor | NGM Biopharmaceuticals, Inc.;630 Gateway Blvd;South San Francisco, California, 94080 |
